Suchergebnisse - "Gopalakrishnan, Sathej"

PubPharm (32)

1

Asia-Inclusive Global Development of Enpatoran : Results of an Ethno-Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial

enthalten in: Clinical pharmacology and therapeutics | 2024

von Klopp-Schulze, L. | Gopalakrishnan, S. | Yalkinoglu, �. | +10

2

Venetoclax in biomarker-selected multiple myeloma patients : Impact of exposure on clinical efficacy and safety

enthalten in: Hematological oncology | 2024

von Badawi, M. | Coppola, S. | Eckert, D. | +8

3

Venetoclax in biomarker‐selected multiple myeloma patients : Impact of exposure on clinical efficacy and safety

enthalten in: Hematological Oncology | 2024

von Badawi, M. | Coppola, S. | Eckert, D. | +8

4

Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective

enthalten in: Xenobiotica; the fate of foreign compounds in biological systems | 2023

von Scheible, H. | Schieferstein, H. | Schmidt, R. | +10

5

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia : A Pooled Analysis of Six Clinical Studies

enthalten in: HemaSphere | 2023

von Gopalakrishnan, S. | Menon, R. | Suleiman, A. | +10

6

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia : A Pooled Analysis of Six Clinical Studies

enthalten in: HemaSphere | 2023

von Gopalakrishnan, S. | Menon, R. | Suleiman, A. | +10

7

Alternatives to rifampicin : A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies

enthalten in: Clinical and translational science | 2022

von Bolleddula, J. | Gopalakrishnan, S. | Hu, P. | +2

8

Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

enthalten in: Hematological oncology | 2022

von Brackman, D. | Eckert, D. | Menon, R. | +9

9

Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials

enthalten in: Clinical and translational science | 2022

von Muensterman, E. | Engelhardt, B. | Gopalakrishnan, S. | +2

10

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials

enthalten in: Clinical and Translational Science | 2022

von Muensterman, E. | Engelhardt, B. | Gopalakrishnan, S. | +2